Discussion

The rise of biological therapeutics and the advent of cell and gene therapies have presented new challenges in analytical methodology. With the majority of new drugs being produced in mammalian cell lines and novel treatments based on cell and gene therapies rapidly expanding, there is a need to fully characterise complex biologics and cells at the proteomic level. Traditional approaches such as western blotting, ELISA and flow cytometry lack high multiplexing potential and require specific antibodies to identify proteins of interest. inCYT employs high-resolution tandem mass spectrometry, label-free relative quantitation and an advanced computer algorithm to identify proteins with high confidence. It is possible with inCYT to routinely identify 3000 to 4000 proteins from a whole cell lysate or tissue lysate and determine their relative abundance. Multiple protein expression profiles for various drug treatments or cell growth conditions can be rapidly and accurately compared using inCyt.